KBI Biopharma, Inc., a JSR Life Sciences company, launched SUREmAb, an offering built on KBI’s SUREtechnology Platform designed for optimized, safe, and cost-efficient monoclonal antibody (mAb) development and manufacturing. SUREmAb is a vertically integrated global offering designed to minimize development timelines for global biopharmaceutical manufacturers, delivering research cell bank (RCB) development in as little as nine weeks and the ability for customers to move from DNA to GMP drug ...